Last reviewed · How we verify
Atlizumab
Atlizumab is a Small molecule drug developed by Peking University Third Hospital. It is currently FDA-approved. Also known as: conventional antitumor treatmen.
At a glance
| Generic name | Atlizumab |
|---|---|
| Also known as | conventional antitumor treatmen |
| Sponsor | Peking University Third Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease (PHASE1, PHASE2)
- Tocilizumab in Lung Transplantation (PHASE2)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission (NA)
- Neutralizing Interleukin (IL)-6 (PHASE2)
- ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atlizumab CI brief — competitive landscape report
- Atlizumab updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Atlizumab
What is Atlizumab?
Atlizumab is a Small molecule drug developed by Peking University Third Hospital.
Who makes Atlizumab?
Atlizumab is developed and marketed by Peking University Third Hospital (see full Peking University Third Hospital pipeline at /company/peking-university-third-hospital).
Is Atlizumab also known as anything else?
Atlizumab is also known as conventional antitumor treatmen.
What development phase is Atlizumab in?
Atlizumab is FDA-approved (marketed).
Related
- Manufacturer: Peking University Third Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: conventional antitumor treatmen
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing